our analysis showing an in frame deletion. Carrier determination in families in which DMD is caused by a deletion using linkage, dosage, or breakpoint analysis is discussed.
The introduction of DNA analysis for the diagnosis of Duchenne muscular dystrophy (DMD) and its milder allelic form Becker muscular dystrophy (BMD) has resulted in substantial progress in carrier determination and prenatal diagnosis for affected families. We describe here our methods of DNA diagnosis of DMD/BMD and discuss, in particular, the advantages and problems of the application of the polymerase chain reaction (PCR) for genomic diagnosis of this disease. A summary of the DNA analysis data collected during the last two years in the GDR and selected regions of Czechoslovakia and Hungary is given.
Materials and methods

MOLECULAR PROBES
We used the cDNA probes cf56a and b, which correspond to exons in the central region of the gene,'2 and the PCR primers described by Chamber (f) The control PCR productfrom the undeleted part using oligonucleotides 2 and 3. (g) The PCR product ofa person cariying this particular deletion using oligonucleotides I and 3. (h) The theoretical PCR product ofa person without a deletion using oligonucleotides I and 3. Because the distance in undeleted DNA is probably some hundred kbp, the PCR product is not detectable. altered restriction fragments resulting from a deletion is another way, which is, however, based on Southern analysis. An example of a very fast and technically unambiguous method for carrier determination using PCR is shown in fig 2. Cloning and sequencing of the breakpoint in a DMD/BMD patient allows PCR bridging the deletion. Only the DNA of family members who have a deletion like the affected patient gives a PCR product (fig 2g) . In normal cases, such as the grandmother, the grandfather, and the mother in this particular family, no PCR product is detectable because the distance between the two oligonucleotide primers probably covers some hundred kbp (fig 2h) . 
